Skip to main content
Erschienen in: Clinical Drug Investigation 1/2000

01.07.2000 | Clinical Pharmacokinetics

In vitro Comparison of Three Salbutamol-Containing Multidose Dry Powder Inhalers

Buventol Easyhaler®, Inspiryl Turbuhaler® and Ventoline Diskus®

verfasst von: Anne Palander, Terhi Mattila, Mika Karhu, Esa Muttonen

Erschienen in: Clinical Drug Investigation | Ausgabe 1/2000

Einloggen, um Zugang zu erhalten

Abstract

Objective: To compare the in vitro drug delivery characteristics of three salbutamol-containing multidose dry powder inhalers, Buventol Easyhaler®, Inspiryl Turbuhaler® and Ventoline Diskus®.
Materials and Methods: Dose accuracy and consistency, fine particle dose (FPD)/fine particle fraction (FPF), and mass median aerodynamic diameter (MMAD) [measured by Multi-Stage Liquid Impinger] were determined for each inhaler at variable airflow rates (30 and 60 L/min) and at ‘equivalent’ flow rates (corresponding to a 4kPa pressure drop).
Results: Dose accuracy and consistency (expressed as percentage of label claim) of Easyhaler® (mean 95%, SD <4.5% at 30 to 60 L/min) compared favourably with that of Turbuhaler® (mean 88%, SD 19% at 60 L/min) and Diskus® (mean 93%, SD 8% at 90 L/min). The FPF at an ‘equivalent’ flow rate was 21% for Easyhaler®, 24% for Turbuhaler® and 20% for Diskus®. The FPF of Turbuhaler® was strongly influenced by flow rate (12 to 24% at 30 to 60 L/min), whereas the FPF of Easyhaler® (16 to 23% at 30 to 60 L/min) and Diskus® (15 to 21% at 30 to 90 L/min) was less variable. MMAD values for Easyhaler® and Turbuhaler® were stable at flow rates of 30 to 60 L/min, whereas the particle size distribution for Diskus® was more dependent on flow rate. Easyhaler® had a considerably lower MMAD than Turbuhaler® at flow rates of 30 to 60 L/min.
Conclusions: This study demonstrated favourable dose delivery and consistency with Buventol Easyhaler® compared with Inspiryl Turbuhaler® and Ventoline Diskus®. Delivered dose and FPF showed less flow dependency with Easyhaler® and Diskus® than with Turbuhaler®.
Literatur
2.
Zurück zum Zitat Timsina MP, Martin GP, Marriott C, et al. Drug delivery to the respiratory tract using dry powder inhalers. Int J Pharm 1994; 101: 1–13CrossRef Timsina MP, Martin GP, Marriott C, et al. Drug delivery to the respiratory tract using dry powder inhalers. Int J Pharm 1994; 101: 1–13CrossRef
3.
Zurück zum Zitat Vidgren M, Kärkkainen A, Karjalainen P, et al. Effect of powder inhaler design on drug deposition in the respiratory tract. Int J Pharm 1988; 42: 211–6CrossRef Vidgren M, Kärkkainen A, Karjalainen P, et al. Effect of powder inhaler design on drug deposition in the respiratory tract. Int J Pharm 1988; 42: 211–6CrossRef
4.
Zurück zum Zitat Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers: implications for in vitro testing. J Aerosol Med 1993; 6: 99–110PubMedCrossRef Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers: implications for in vitro testing. J Aerosol Med 1993; 6: 99–110PubMedCrossRef
5.
Zurück zum Zitat Hallworth GN, Andrews UG. Size analysis of suspension inhalation aerosols by inertial separation methods. J Pharm Pharmacol 1976; 28: 898–907PubMedCrossRef Hallworth GN, Andrews UG. Size analysis of suspension inhalation aerosols by inertial separation methods. J Pharm Pharmacol 1976; 28: 898–907PubMedCrossRef
6.
Zurück zum Zitat Hickey AJ, Concessio NM, Van Oort MM, et al. Factors influencing the dispersion of dry powder as aerosols. Pharm Technol 1994; 8: 58–64 Hickey AJ, Concessio NM, Van Oort MM, et al. Factors influencing the dispersion of dry powder as aerosols. Pharm Technol 1994; 8: 58–64
7.
Zurück zum Zitat Moren F. Towards satisfactory in vitro testing requirements for single and multi-dose powder inhalers. J Pharm Sci 1992; 3: 123–9 Moren F. Towards satisfactory in vitro testing requirements for single and multi-dose powder inhalers. J Pharm Sci 1992; 3: 123–9
8.
Zurück zum Zitat Rogers DF, Ganderton D. Determining the equivalence of inhaled medications. Respir Med 1995; 89: 253–61PubMedCrossRef Rogers DF, Ganderton D. Determining the equivalence of inhaled medications. Respir Med 1995; 89: 253–61PubMedCrossRef
9.
Zurück zum Zitat European Pharmacopoeia. 3rd ed. Supplement. Strasbourg: Council of Europe, 1999 European Pharmacopoeia. 3rd ed. Supplement. Strasbourg: Council of Europe, 1999
10.
Zurück zum Zitat Vidgren M, Silvasti M, Vidgren P, et al. Easyhaler® multiple dose powder inhaler —practical and effective alternative to the pressurized MDI. Aerosol Sci Technol 1995; 22: 335–45CrossRef Vidgren M, Silvasti M, Vidgren P, et al. Easyhaler® multiple dose powder inhaler —practical and effective alternative to the pressurized MDI. Aerosol Sci Technol 1995; 22: 335–45CrossRef
11.
Zurück zum Zitat Wetterlin K. Turbuhaler: a new powder inhaler for administration of drugs to the airways. Pharm Res 1988; 5: 506–8PubMedCrossRef Wetterlin K. Turbuhaler: a new powder inhaler for administration of drugs to the airways. Pharm Res 1988; 5: 506–8PubMedCrossRef
12.
Zurück zum Zitat Brindley A, Sumby BS, Smith IJ, et al. Design, manufacture and dose consistency of the Serevent Diskus inhaler. Pharm Technol Eur 1995; 7: 14–22 Brindley A, Sumby BS, Smith IJ, et al. Design, manufacture and dose consistency of the Serevent Diskus inhaler. Pharm Technol Eur 1995; 7: 14–22
13.
Zurück zum Zitat Persson G, Wiren JE. The bronchodilator response from inhaled terbutaline is influenced by the mass of small particles: a study on a dry powder inhaler (Turbohaler). Eur Respir J 1989; 2: 253–6PubMed Persson G, Wiren JE. The bronchodilator response from inhaled terbutaline is influenced by the mass of small particles: a study on a dry powder inhaler (Turbohaler). Eur Respir J 1989; 2: 253–6PubMed
14.
Zurück zum Zitat Palander A, Halme A, Kananen M, et al. In vitro performance of inhalers: salbutamol-containing dry powder products. J Aerosol Med 1999; 12: 113 Palander A, Halme A, Kananen M, et al. In vitro performance of inhalers: salbutamol-containing dry powder products. J Aerosol Med 1999; 12: 113
15.
Zurück zum Zitat Bisgaard H. What dose fraction represents the respirable dose? Respir Med 1997; 91Suppl. A: 20–1PubMedCrossRef Bisgaard H. What dose fraction represents the respirable dose? Respir Med 1997; 91Suppl. A: 20–1PubMedCrossRef
16.
Zurück zum Zitat Hill LS, Slater AL. A comparison of the performance of two modern multidose dry powder asthma inhalers. Respir Med 1998; 92: 105–10PubMedCrossRef Hill LS, Slater AL. A comparison of the performance of two modern multidose dry powder asthma inhalers. Respir Med 1998; 92: 105–10PubMedCrossRef
17.
Zurück zum Zitat Hindle M, Byron PR. Dose emissions from marketed dry powder inhalers. Int J Pharm 1995; 116: 169–77CrossRef Hindle M, Byron PR. Dose emissions from marketed dry powder inhalers. Int J Pharm 1995; 116: 169–77CrossRef
18.
Zurück zum Zitat Malton A, Sumby BS, Smith IJ. A comparison of in vitro drug delivery from two multidose powder inhalation devices. Eur J Clin Res 1995; 7: 177–93 Malton A, Sumby BS, Smith IJ. A comparison of in vitro drug delivery from two multidose powder inhalation devices. Eur J Clin Res 1995; 7: 177–93
19.
Zurück zum Zitat Prime D, Slater AL, Haywood PA, et al. Assessing dose delivery from the Flixotide Diskus inhaler —a multidose powder inhaler. Pharm Technol Eur 1996; 8: 23–8 Prime D, Slater AL, Haywood PA, et al. Assessing dose delivery from the Flixotide Diskus inhaler —a multidose powder inhaler. Pharm Technol Eur 1996; 8: 23–8
20.
Zurück zum Zitat Steckel H, Müller BW. In vitro evaluation of dry powder inhalers I: drug deposition of commonly used devices. Int J Pharm 1997; 154: 19–29CrossRef Steckel H, Müller BW. In vitro evaluation of dry powder inhalers I: drug deposition of commonly used devices. Int J Pharm 1997; 154: 19–29CrossRef
21.
Zurück zum Zitat Olsson B, Asking L. Critical aspects of the function of inspiratory flow driven inhalers. J Aerosol Med 1994; 7Suppl. 1: S43–7PubMed Olsson B, Asking L. Critical aspects of the function of inspiratory flow driven inhalers. J Aerosol Med 1994; 7Suppl. 1: S43–7PubMed
Metadaten
Titel
In vitro Comparison of Three Salbutamol-Containing Multidose Dry Powder Inhalers
Buventol Easyhaler®, Inspiryl Turbuhaler® and Ventoline Diskus®
verfasst von
Anne Palander
Terhi Mattila
Mika Karhu
Esa Muttonen
Publikationsdatum
01.07.2000
Verlag
Springer International Publishing
Erschienen in
Clinical Drug Investigation / Ausgabe 1/2000
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI
https://doi.org/10.2165/00044011-200020010-00004

Weitere Artikel der Ausgabe 1/2000

Clinical Drug Investigation 1/2000 Zur Ausgabe